Pfizer, Inc. (NYSE:PFE) has been assigned a $39.00 price target by stock analysts at Jefferies Group LLC in a research report issued on Thursday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target would suggest a potential upside of 10.26% from the company’s current price.
PFE has been the subject of a number of other reports. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and increased their price target for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. UBS AG reissued a “buy” rating and set a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $38.48.
Pfizer (NYSE:PFE) opened at $35.37 on Thursday. The firm has a market capitalization of $211,960.00, a PE ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a one year low of $30.51 and a one year high of $36.78.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.61 earnings per share. research analysts forecast that Pfizer will post 2.6 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Pfizer, Inc. (PFE) Given a $39.00 Price Target by Jefferies Group LLC Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/18/pfizer-inc-pfe-given-a-39-00-price-target-by-jefferies-group-llc-analysts.html.
In related news, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 197,168 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the transaction, the chief executive officer now directly owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. In the last three months, insiders sold 374,621 shares of company stock worth $12,796,098. 0.06% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Pfizer by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after purchasing an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. grew its stake in Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after purchasing an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after acquiring an additional 1,085,437 shares in the last quarter. 69.36% of the stock is currently owned by institutional investors.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.